Viemed Healthcare’s Market Performance in Fluctuating Financial Landscape

Photo of author
Written By Kevin MacDonald

Viemed Healthcare, Inc. (NASDAQ: VMD) has been showing bullish trends, primarily driven by strong top-line sales growth. The company’s shares have appreciated nearly 50% over the past 5 years.

However, recent developments have caused a shift in perspective following missed earnings and sales targets in Q3 of the last fiscal year.

Technical Barriers and Stock Valuation

Viemed’s inability to breach long-term resistance levels, notably around the $10 mark, has been a critical factor in reassessing the stock’s potential.

Credit: DepositPhotos

Despite a recovery following the Q3 earnings report, the stock has faced a 17% decline over the past six weeks.

Growth and Earnings Projections

Historically, Viemed has demonstrated good annual growth, averaging over 25% in top-line expansion. However, future forecasts have adjusted these expectations downward, with an anticipated growth of 18% in 2024, followed by a further slowdown to 12%.

These revised projections have subsequently impacted the company’s forward GAAP multiple for fiscal 2024, increasing it to 22 and reflecting a less attractive earnings yield of 4.55%.

This yield is narrowly lower than that of the 10-year US Treasury bond, which offers slightly higher returns with significantly lower risk.

Viemed’s Strategic Initiatives and Technological Advancements

Viemed continues to invest in its proprietary ‘Engage Care Manager’ platform, which is critical to its strategy of reaching more patients and improving care through technology.

The company has undertaken significant restructuring of its sales force to optimize coverage and effectiveness. The potential of this platform to enhance patient care through software and machine learning is a key focus as the company heads into its Q1 earnings report for fiscal 2024.

Financial Health and Profitability Metrics

In fiscal 2023, Viemed reported a gross profit margin of 61.63% but a considerably lower net income margin of 5.6%.

This discrepancy highlights the challenges Viemed faces in terms of operational efficiency, particularly due to elevated capital expenditure needs.

Despite these challenges, the company’s strong balance sheet, with $113.9 million in shareholder equity and only $6 million in long-term debt, provides a sturdy foundation for future growth and financial stability.

Regulatory Environment and Market Opportunities

Viemed’s operational strategy is significantly influenced by regulatory developments, particularly those related to Medicare reimbursements and the Center for Program Integrity’s policies.

The end of the 75-25 blended rates and other regulatory adjustments are expected to continue providing favorable conditions for Viemed, especially in expanding access to care for chronic obstructive pulmonary disease (COPD) patients.

Despite potential competition from new treatments and drugs, Viemed’s niche in respiratory and sleep care remains robust.

Viemed’s Market Position and Future Outlook

While the stock currently trades below its 2020 highs, the fundamentals of Viemed’s business—coupled with its technological and regulatory strategies—indicate potential for future appreciation.

Credit: DepositPhotos

The company’s approach to managing its balance sheet, coupled with strategic investments in growth areas, suggests that while the short-term outlook may appear bearish due to recent downgrades, the long-term prospects remain promising.

Potential Rebound Despite Bearish Performance

Viemed Healthcare stands at a critical juncture where its ability to leverage technological advancements and navigate a complex regulatory landscape will determine its market position.

As analysts and investors await the upcoming earnings report, the focus will be on whether Viemed can capitalize on these strategies to reverse recent bearish trends and reposition itself for growth.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.